FDA accepts Genentech’s Gazyva application for SLE, what it means for lupus treatment
FDA accepts Genentech’s Gazyva filing for systemic lupus erythematosus. Read what the ALLEGORY data could mean for lupus treatment in 2026.
Pharma & Biotech
Pharma & Biotech
Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate
Lantern Pharma’s LP-300 showed an early EGFR L858R lung cancer signal. Read what the FDA meeting and trial redesign could change next.
Pharma & Biotech
Takara Bio USA unveils AACR benchmark data for Trekker FX, but will cancer labs switch?
Takara Bio USA says Trekker FX outperformed conventional spatial methods in a cancer benchmark study. Read what this could mean for oncology research.
Pharma & Biotech
Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?
Palleon Pharmaceuticals has moved E-688/HLX316 into human testing. Read why this B7-H3 sialidase could reshape immuno-oncology.
Pharma & Biotech
Could Entos Pharmaceuticals’ Fusogenix platform open a real path to treatment in L-CMD?
Entos Pharmaceuticals and the L-CMD Research Foundation are targeting a curative L-CMD therapy. Read what this could change for rare disease treatment.
Pharma & Biotech
What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.
Pharma & Biotech
Can Debiopharm turn a Fast Track win into a real ovarian cancer breakthrough?
Debiopharm’s ovarian cancer combo won FDA Fast Track after AACR 2026 data. Read what it means for DDR therapy, biomarkers, and clinical risk.
Pharma & Biotech
Why CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy strategies
Discover how CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy and expand checkpoint treatment potential.
Pharma & Biotech
Akari Therapeutics Plc advances AKTX-101 as RNA splicing ADC targets TROP2 resistance in oncology
Discover how AKTX-101 could redefine TROP2 ADC resistance strategies in oncology. Read the full analysis now.
Pharma & Biotech
Why Oragenics, Inc.’ ONP-002 Phase IIa progress could redefine concussion treatment pathways
Can ONP-002 become the first approved concussion drug? Explore Oragenics’ Phase IIa progress and what it means for mTBI treatment.